Name: 글로벌 시장 동향
SKU: PH8610
Availability: InStock

보고서 요약(국문)

보고서 개요
전 세계 대사 기능 장애 관련 지방간염(MASHL) 치료 시장은 2023년 16억 7천만 달러에 달했으며, 2024년부터 2031년까지 연평균 21.8%의 성장률을 기록하며 2031년에는 76억 4천만 달러에 이를 것으로 예상됩니다.
대사 기능 장애 관련 지방간염은 대사 기능 장애 관련 지방간 질환(MASHL)의 진행된 단계입니다. 이 질환은 알코올 섭취량이 적더라도 간에 염증을 일으키고 손상을 유발합니다. 지방간 질환이 있는 사람은 간에 과도한 지방이 축적되기 시작합니다. 이는 항상 문제를 일으키는 것은 아니지만, 문제가 발생할 경우 지방간염이라고 합니다.
대사 기능 장애 관련 지방간염(이전에는 비알코올성 지방간염 또는 NASH로 알려짐)은 지방간 질환의 한 유형입니다. 대사 장애 관련 지방간염(MASH)은 비만이나 당뇨병과 같은 대사 장애로 인해 간에 독성 지방이 축적되어 발생하는 경우가 많습니다. MASH 증상은 종종 무증상이거나 비특이적이어서 진단이 어렵습니다. 따라서 MASH 환자는 질병이 상당히 진행될 때까지 자신의 상태를 인지하지 못하는 경우가 많습니다. 대부분의 사람들에게 간에 지방이 축적되는 것은 바람직하지는 않지만 문제를 일으키지는 않습니다. 그러나 일부 사람들에게서는 지방이 간세포에 독성을 나타내어 염증과 세포 손상을 유발할 수 있습니다.
시장 동향: 성장 동력
대사 장애 관련 지방간염(MASLD) 유병률 증가
전 세계 대사 장애 관련 지방간염(MASH) 치료 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 대사 장애 관련 지방간염(MASLD)의 유병률 증가가 시장 성장을 견인하고 있습니다.
또한, 기술 발전으로 치료 수요가 증가할 것으로 예상됩니다. 예를 들어, 미국 국립보건원(NIH)에 따르면 전 세계 성인 인구의 약 30%가 MASLD를 앓고 있는 것으로 추정됩니다. 대사 기능 장애 관련 지방간염(MASLD)의 유병률 증가는 비만 및 비만 관련 질환의 유병률 증가와 밀접한 관련이 있습니다. MASLD의 더 심각한 형태인 MASLD는 조직학적으로 소엽 염증과 간세포 풍선 변성을 특징으로 하며, 섬유화 진행 위험이 더 높습니다.
아시아 다기관 코호트 연구에서 간 생검을 받은 MASLD 환자의 63%에서 MASH가 발견되었습니다. 간 생검 적응증이 없는 MASLD 환자에서는 MASH 유병률이 7%입니다. 심혈관 질환(CVD)은 MASLD 환자의 주요 사망 원인이지만, 간 섬유화가 심할수록 간 관련 사망 위험이 증가하며, 섬유화 단계가 진행될수록 위험은 기하급수적으로 증가합니다. 지방간 질환(SLD)은 만성 간 질환 부담에 상당한 영향을 미칩니다. 본원 간 클리닉 환자의 62%가 MASLD였으며, 다른 만성 간 질환 환자의 47%에서도 심각한 지방간이 관찰되었습니다.

미국에서 MASH는 성인 간 이식의 주요 원인 중 하나이며, 간세포암(HCC) 환자의 간 이식에도 주요 원인으로 작용합니다. MASH 및 HCC를 포함한 합병증의 부담은 향후 몇 년 동안 계속 증가할 것으로 예상됩니다.
제한 요인
높은 치료 비용, 질병에 대한 인식 부족, 신약 승인에 대한 엄격한 규제 요건 등이 시장 성장을 저해할 것으로 예상됩니다.
시장 세분화 분석
전 세계 대사 기능 장애 관련 지방간염 치료 시장은 치료법, 최종 사용자 및 지역별로 세분화됩니다.
약물 부문은 전 세계 대사 기능 장애 관련 지방간염 치료 시장의 약 54.3%를 차지합니다.
약물 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이 부문에서는 기술 발전과 민간 제약 회사의 약물 치료 임상 시험 투자 증가가 시장 성장을 견인할 것입니다. 대사 기능 장애 관련 지방간염 치료에 사용되는 약물은 레즈디프라(Rezdiffra)이며, 최근 세 가지 약물이 치료용으로 승인되었습니다. 예를 들어, 2024년 3월 FDA는 대사 기능 장애 관련 지방간염(MASH) 치료제를 최초로 승인했습니다. 이 승인은 미국 성인의 약 5%에게 영향을 미치는 것으로 추정되는 이 분야에 진출하려는 많은 다른 회사들에게 중요한 기준이 되었습니다. 레즈디프라(Rezdiffra)는 3상 임상시험에서 MASH 증상 완화와 섬유화 개선이라는 두 가지 목표를 모두 달성한 최초의 약물입니다.
시장 지역별 점유율
북미는 전 세계 MASH 치료제 시장의 약 43.2%를 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 기술 발전과 연구 자금 지원이 시장 성장을 견인하고 있습니다.
예를 들어, 2024년 6월 일라이 릴리(Eli Lilly)는 2상 SYNERGY-NASH 연구의 중간 단계에서 환자의 50% 이상에서 섬유화 악화 없이 MASH가 소실되는 결과를 얻었다고 발표했습니다. 52주 시점에서 5mg 티르제파티드를 투여받은 환자의 51.8%에서 섬유증 악화 없이 대사 기능 장애 관련 지방간염(MASH)이 소실되었습니다. 이 비율은 10mg 및 15mg 투여군에서 각각 62.8% 및 73.3%로 증가한 반면, 위약 투여군에서는 13.2%만이 최종 목표에 도달했습니다.
또한, 2024년 5월 미국 바이오제약 회사인 89bio는 대상성 간경변증을 동반한 대사 기능 장애 관련 지방간염(MASH) 치료를 위한 페고자페르민의 3상 ENLIGHTEN-Cirrhosis 임상시험을 시작했습니다.

시장 세분화
치료 유형별
• 약물별
• 레즈디프라
• 요법별
• 피트산 기반 나노 의약품 요법
• 체중 관리
• 당뇨병 관리
• 규칙적인 운동
• 기타
최종 사용자별
• 병원
• 전문 클리닉
• 가정 간호
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
시장 경쟁 환경
전 세계 대사 기능 장애 관련 지방간염 치료 시장의 주요 글로벌 기업으로는 Madrigal Pharmaceuticals, Simson Pharma Limited, Dr. Reddy’s Laboratories Ltd., Thermo Fisher Scientific Inc., Biosynth 등이 있습니다. Affgility Solutions, Conscientia Industrial Co. Ltd., Smolecule Inc., 89 Bio Inc., Sandoo Pharmaceuticals and Chemicals Co. Ltd. 등이 있습니다.
주요 개발 사항
• 2024년 8월, Altimmune의 실험 치료제인 펨비두티드(pemvidutide)는 1상 임상시험의 일환으로 대사 기능 장애 관련 지방간 질환(MASLD)을 가진 과체중 또는 비만 환자에서 간 지방과 염증, 체중을 유의미하게 감소시키는 효과를 보였습니다. 현재 IMPACT(NCT05989711)라는 2b상 임상시험에서 대사 기능 장애 관련 지방간염(MASH)을 가진 최대 190명의 성인을 대상으로 펨비두티드와 위약을 비교하고 있습니다.

• 2024년 7월, 서북공업대학의 취용취안/톈즈민 연구팀과 공군의과대학의 류레이/자오쥔룽 연구팀이 발표한 연구 논문에 따르면, 피틴산 기반 나노의약품이 대사 기능 장애 관련 간염 치료에 유망한 것으로 나타났습니다. 세륨은 강력한 항산화 및 항염증 작용뿐 아니라 간 친화성과 우수한 생체 안전성을 지니고 있어 간 질환 치료에 큰 잠재력을 보여줍니다.
• 2024년 7월, 단핵구 유래 대식세포가 MASH 관련 간 섬유화에 관여하는 것으로 밝혀졌지만, 그 정확한 역할과 기저 분화 메커니즘은 아직 명확히 규명되지 않았습니다. 본 연구에서는 이 과정의 핵심 조절인자인 장쇄 포화지방산-Egr2 경로를 밝혀냈습니다. 연구 결과는 전사 인자 Egr2가 MASH 간에서 단핵구가 간 지질 관련 대식세포(hLAM)로 분화하는 원동력임을 확인했습니다.
이 보고서를 구매해야 하는 이유?

• 치료법, 최종 사용자 및 지역별 글로벌 대사 기능 장애 관련 지방간염 치료 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.
• 모든 세그먼트를 포함한 글로벌 대사 기능 장애 관련 지방간염(MASH) 치료 시장의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 Excel 파일로 제공합니다.

글로벌 대사 기능 장애 관련 지방간염 치료 시장 보고서는 약 51개의 표, 54개의 그림, 181페이지 분량입니다.
주요 고객 (2024년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market reached US$ 1.67 billion in 2023 and is expected to reach US$ 7.64 billion by 2031, growing at a CAGR of 21.8% during the forecast period 2024-2031.
Metabolic dysfunction-associated steatohepatitis is the advanced stage of metabolic dysfunction-associated steatotic liver disease (MASLD). This condition causes inflammation and damages the patient’s liver — again, despite low alcohol use. If one has steatotic (fatty) liver disease, the body will begin to store excess fat in the liver. This doesn’t always cause problems for people. But when it does, it’s called steatohepatitis.
Metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis or NASH) is a type of fatty liver disease. It often develops due to a metabolic disorder, such as obesity or diabetes, resulting in a toxic buildup of fat in the liver. MASH symptoms are often silent or nonspecific, making it difficult to diagnose. As a result, MASH patients can remain unaware of their condition until the late stages of the disease. For most people, a buildup of fat in the liver, while not ideal, causes no problems. But in some people, the fat can become toxic to liver cells, causing inflammation and cell damage.
Market Dynamics: Drivers
Increasing prevalence of metabolic dysfunction-associated steatotic liver disease
The demand for the global metabolic dysfunction-associated steatohepatitis (MASH) treatment market is driven by multiple factors. The rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) propels the market growth.
Furthermore, the demand for treatment will be fueled by the increase in technological advancements. For instance, according to nih.gov, MASLD has been estimated to affect 30% of the adult population worldwide. The increasing prevalence of MASLD parallels the increasing prevalence of obesity and obesity-related diseases. Metabolic dysfunction-associated steatohepatitis is the more severe form of MASLD, is defined histologically by the presence of lobular inflammation and hepatocyte ballooning, and is associated with a greater risk of fibrosis progression.
MASH has been found in 63% of patients with MASLD undergoing liver biopsy in an Asian multi-center cohort. Among patients with MASLD without an indication for liver biopsy, the prevalence of MASH is 7%. While CVD is the leading cause of mortality in patients with MASLD, those with more severe liver fibrosis are at increased risk of liver-related mortality, with the risk increasing exponentially with fibrosis stage. Steatotic liver disease (SLD) contributes significantly to the burden of chronic liver disease. While 62% of patients seen in our liver clinic had MASLD, 47% of patients with other chronic liver diseases had significant hepatic steatosis.
In the United States, MASH has become one of the leading causes of adult liver transplantation and among patients with HCC undergoing liver transplantation. The burden of MASLD and its complications, including HCC, is projected to continue to increase in the coming years.
Restraints
Factors such as the high cost associated with the treatment, lack of awareness among people, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market.
Market Segment Analysis
The global metabolic dysfunction-associated steatohepatitis treatment market is segmented based on treatment, end-user, and region.
The segment by drug accounted for approximately 54.3% of the global metabolic dysfunction-associated steatohepatitis treatment market share
The drugs segment is expected to hold the largest market share over the forecast period. In this segment, the technological developments, and rising funds for private manufacturers for drug treatment clinical trials would drive this market. The drug that is used for the treatment of metabolic dysfunction-associated steatohepatitis is rezdiffra and three drugs were approved recently for the usage of treatment.
For instance, in March 2024, the FDA approved the first drug for metabolic dysfunction-associated steatohepatitis treatment. Its approval sets the bar for many other companies that are also eying the field, which is estimated to affect about 5% of adults in the U.S. Rezdiffra was the first drug to have met both goals of MASH resolution and fibrosis improvement in a phase 3 trial.
Market Geographical Share
North America accounted for approximately 43.2% of the global metabolic dysfunction-associated steatohepatitis treatment market share
North America region is expected to hold the largest market share over the forecast period. The technological advancements, and funding allotted for research works, help to propel the market.
For instance, in June 2024, Eli Lilly announced that they achieved an absence of metabolic dysfunction-associated steatohepatitis without the worsening of fibrosis in more than 50% of patients in a mid-stage study from their Phase II SYNERGY-NASH study. At 52 weeks, 51.8% of patients treated with 5-mg tirzepatide saw an absence of metabolic dysfunction-associated steatohepatitis (MASH) without the worsening of fibrosis. This proportion increased to 62.8% and 73.3% in the 10-mg and 15-mg dose groups, respectively, while only 13.2% of placebo counterparts reached the endpoint.
Moreover, in May 2024, US-based biopharmaceutical company 89bio began the Phase III ENLIGHTEN-Cirrhosis clinical trial of pegozafermin for treating metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis.
Market Segmentation
By Treatment
• By Drug
• Rezdiffra
• By Therapy
• Phytic Acid Based Nano-Medicine Therapy
• Weight Management
• Diabetes Control
• Regular Exercise
• Others
By End-User
• Hospitals
• Specialty Clinics
• Homecare
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Market Competitive Landscape
The major global players in the global metabolic dysfunction-associated steatohepatitis treatment market include Madrigal Pharmaceuticals, Simson Pharma Limited, Dr. Reddy’s Laboratories Ltd., Thermo Fisher Scientific Inc., Biosynth, Affgility Solutions, Conscientia Industrial Co. Ltd., Smolecule Inc., 89 Bio Inc., and Sandoo Pharmaceuticals and Chemicals Co. Ltd. among others.
Key Developments
• In August 2024, Altimmune’s experimental therapy with pemvidutide significantly reduced liver fat and inflammation, as well as body weight, among overweight or obese people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease as a part of Phase I clinical trials. A Phase 2b trial called IMPACT (NCT05989711) now is testing pemvidutide against a placebo in up to 190 adults with metabolic dysfunction-associated steatohepatitis (MASH).
• In July 2024, according to a research paper published by the Qu Yongquan/Tian Zhimin team from Northwestern Polytechnical University, and the Liu Lei/Zhao Junlong team from Air Force Medical University, phytic acid-based nanomedicine shows promise for metabolic dysfunction-associated sttraileatohepatitis therapy. Due to cerium's significant antioxidant and anti-inflammatory activities, as well as its hepatophilicity and good biosafety, it shows great potential in liver disease treatment.
• In July 2024, Monocyte-derived macrophages have been implicated in MASH-associated liver fibrosis, yet their precise roles and the underlying differentiation mechanisms remain elusive. In this study, a key orchestrator of this process is unveiled: long chain saturated fatty acid-Egr2 pathway. The findings identify the transcription factor Egr2 as the driving force behind monocyte differentiation into hepatic lipid-associated macrophages (hLAMs) within MASH liver.
Why Purchase the Report?
• To visualize the global metabolic dysfunction-associated steatohepatitis treatment market segmentation based on treatment, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global metabolic dysfunction-associated steatohepatitis (MASH) treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global metabolic dysfunction-associated steatohepatitis treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by End-User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of MASLD
4.1.1.2. Technological Advancement
4.1.2. Restraints
4.1.2.1. High Cost Associated with the Treatment
4.1.2.2. Lack of Awareness
4.1.2.3. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Treatment
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
6.1.2. Market Attractiveness Index, By Treatment
6.2. Drug*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Therapy
6.4. Weight Management
6.5. Diabetes control
6.6. Regular Exercise
6.7. Foscarnet
6.8. Others
7. By End-User
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Homecare
7.5. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. The U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. UK
8.3.5.3. France
8.3.5.4. Italy
8.3.5.5. Spain
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Madrigal Pharmaceuticals *
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Simson Pharma Limited
10.3. Dr. Reddy’s Laboratories Ltd.
10.4. Thermo Fisher Scientific Inc.
10.5. Biosynth
10.6. Affgility Solutions
10.7. Conscientia Industrial Co. Ltd.
10.8. Smolecule Inc.
10.9. 89 Bio Inc.
10.10. Sandoo Pharmaceuticals and Chemicals Co. Ltd. (*LIST NOT EXHAUSTIVE)
11. Appendix
11.1. About Us and Services
11.2. Contact Us

언급된 주요 기업들

Madrigal Pharmaceuticals, 4.	Key Developments, Simson Pharma Limited, Dr. Reddy’s Laboratories Ltd., Thermo Fisher Scientific Inc., Biosynth, Affgility Solutions, Conscientia Industrial Co. Ltd., Smolecule Inc., 89 Bio Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 6 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 8 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Region, 2022-2031 (US$ Million)

Table 10 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 11 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 12 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 13 South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 14 South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 15 South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 16 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 17 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 18 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 21 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Middle East and Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 Middle East and Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Middle East and Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Madrigal Pharmaceuticals: Overview

Table 26 Madrigal Pharmaceuticals: Product Portfolio

Table 27 Madrigal Pharmaceuticals: Key Developments

Table 28 Simson Pharma Limited: Overview

Table 29 Simson Pharma Limited: Product Portfolio

Table 30 Simson Pharma Limited: Key Developments

Table 31 Dr. Reddy’s Laboratories Ltd.: Overview

Table 32 Dr. Reddy’s Laboratories Ltd.: Product Portfolio

Table 33 Dr. Reddy’s Laboratories Ltd.: Key Developments

Table 34 Thermo Fisher Scientific Inc.: Overview

Table 35 Thermo Fisher Scientific Inc.: Product Portfolio

Table 36 Thermo Fisher Scientific Inc.: Key Developments

Table 37 Biosynth: Overview

Table 38 Biosynth: Product Portfolio

Table 39 Biosynth: Key Developments

Table 40 Affgility Solutions: Overview

Table 41 Affgility Solutions: Product Portfolio

Table 42 Affgility Solutions: Key Developments

Table 43 Conscientia Industrial Co. Ltd.: Overview

Table 44 Conscientia Industrial Co. Ltd.: Product Portfolio

Table 45 Conscientia Industrial Co. Ltd.: Key Developments

Table 46 Smolecule Inc.: Overview

Table 47 Smolecule Inc.: Product Portfolio

Table 48 Smolecule Inc.: Key Developments

Table 49 89 Bio Inc: Overview

Table 50 89 Bio Inc: Product Portfolio

Table 51 89 Bio Inc: Key Developments

Table 52 Sandoo Pharmaceuticals: Overview

Table 53 Sandoo Pharmaceuticals: Product Portfolio

Table 54 Sandoo Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 2 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 3 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 4 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Region, 2023 & 2031 (%)

Figure 5 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Y-o-Y Growth, By Treatment, 2023-2031 (%)

Figure 6 Drug Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 7 Therapy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 8 Weight Management Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 9 Diabetes Control Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 10 Regular exercise Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 11 Others Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 12 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 13 Hospitals End-User in Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 14 Speciality Clinics End-User in Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 15 Homecare End-User in Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 16 Others End-User in Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 17 Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 18 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 19 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 20 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 21 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 22 South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 23 South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 24 South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 25 South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 26 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 27 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 28 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 29 Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 30 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 31 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 32 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 33 Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 34 Middle East and Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2031 (US$ Million)

Figure 35 Middle East and Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 36 Middle East and Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 37 Madrigal Pharmaceuticals: Financials

Figure 38 Simson Pharma Limited: Financials

Figure 39 Dr. Reddy’s Laboratories Ltd.: Financials

Figure 40 Thermo Fisher Scientific Inc.: Financials

Figure 41 Biosynth: Financials

Figure 42 Affgility Solutions: Financials

Figure 43 Conscientia Industrial Co. Ltd.: Financials

Figure 44 Smolecule Inc.: Financials

Figure 45 89 Bio Inc: Financials

Figure 46 Sandoo Pharmaceuticals: Financials

전 세계 대사 기능 장애 관련 지방간염(MASH) 치료 – 2024-2031년

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment - 2024-2031